Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.

Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang WJ, Stein RL, Cuny GD, Selkoe DJ.

PLoS One. 2010 May 7;5(5):e10504. doi: 10.1371/journal.pone.0010504.

2.

Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.

Durham TB, Toth JL, Klimkowski VJ, Cao JX, Siesky AM, Alexander-Chacko J, Wu GY, Dixon JT, McGee JE, Wang Y, Guo SY, Cavitt RN, Schindler J, Thibodeaux SJ, Calvert NA, Coghlan MJ, Sindelar DK, Christe M, Kiselyov VV, Michael MD, Sloop KW.

J Biol Chem. 2015 Aug 14;290(33):20044-59. doi: 10.1074/jbc.M115.638205. Epub 2015 Jun 17.

3.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR.

Nature. 2014 Jul 3;511(7507):94-8. doi: 10.1038/nature13297. Epub 2014 May 21.

4.

Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.

Çakir B, Dağliyan O, Dağyildiz E, Bariş İ, Kavakli IH, Kizilel S, Türkay M.

PLoS One. 2012;7(2):e31787. doi: 10.1371/journal.pone.0031787. Epub 2012 Feb 15.

5.

Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.

Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, Hodder P, Leissring MA.

ACS Chem Biol. 2015 Dec 18;10(12):2716-24. doi: 10.1021/acschembio.5b00334. Epub 2015 Sep 30.

PMID:
26398879
6.

Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.

Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA.

J Med Chem. 2013 Mar 28;56(6):2246-55. doi: 10.1021/jm301280p. Epub 2013 Mar 15.

PMID:
23437776
7.

Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.

Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ.

J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5.

8.

Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.

Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington NL, Tang WJ.

Biochemistry. 2008 Dec 2;47(48):12822-34. doi: 10.1021/bi801192h.

9.

Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.

Charton J, Gauriot M, Totobenazara J, Hennuyer N, Dumont J, Bosc D, Marechal X, Elbakali J, Herledan A, Wen X, Ronco C, Gras-Masse H, Heninot A, Pottiez V, Landry V, Staels B, Liang WG, Leroux F, Tang WJ, Deprez B, Deprez-Poulain R.

Eur J Med Chem. 2015 Jan 27;90:547-67. doi: 10.1016/j.ejmech.2014.12.005. Epub 2014 Dec 4.

10.

Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice.

Deprez-Poulain R, Hennuyer N, Bosc D, Liang WG, Enée E, Marechal X, Charton J, Totobenazara J, Berte G, Jahklal J, Verdelet T, Dumont J, Dassonneville S, Woitrain E, Gauriot M, Paquet C, Duplan I, Hermant P, Cantrelle FX, Sevin E, Culot M, Landry V, Herledan A, Piveteau C, Lippens G, Leroux F, Tang WJ, van Endert P, Staels B, Deprez B.

Nat Commun. 2015 Sep 23;6:8250. doi: 10.1038/ncomms9250.

11.

Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.

Cordes CM, Bennett RG, Siford GL, Hamel FG.

Biochem Pharmacol. 2009 Mar 15;77(6):1064-73. doi: 10.1016/j.bcp.2008.12.006. Epub 2008 Dec 27.

PMID:
19154729
12.

Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?

Pivovarova O, Höhn A, Grune T, Pfeiffer AF, Rudovich N.

Ann Med. 2016 Dec;48(8):614-624. Epub 2016 Jun 19. Review.

PMID:
27320287
13.

Non-covalent interaction of ubiquitin with insulin-degrading enzyme.

Saric T, Müller D, Seitz HJ, Pavelic K.

Mol Cell Endocrinol. 2003 Jun 30;204(1-2):11-20.

PMID:
12850277
14.

Insulin-degrading enzyme.

Authier F, Posner BI, Bergeron JJ.

Clin Invest Med. 1996 Jun;19(3):149-60. Review.

PMID:
8724818
15.

Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme.

Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ.

J Biol Chem. 2009 May 22;284(21):14177-88. doi: 10.1074/jbc.M900068200. Epub 2009 Mar 25.

16.

Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.

Shen Y, Joachimiak A, Rosner MR, Tang WJ.

Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11.

17.

Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.

Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR, Tang WJ.

J Biol Chem. 2011 Feb 11;286(6):4670-9. doi: 10.1074/jbc.M110.173252. Epub 2010 Nov 22.

18.

Anion activation site of insulin-degrading enzyme.

Noinaj N, Song ES, Bhasin S, Alper BJ, Schmidt WK, Hersh LB, Rodgers DW.

J Biol Chem. 2012 Jan 2;287(1):48-57. doi: 10.1074/jbc.M111.264614. Epub 2011 Nov 2.

19.

Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.

Guo Q, Manolopoulou M, Bian Y, Schilling AB, Tang WJ.

J Mol Biol. 2010 Jan 15;395(2):430-43. doi: 10.1016/j.jmb.2009.10.072. Epub 2009 Nov 5.

20.

Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Tang WJ.

Trends Endocrinol Metab. 2016 Jan;27(1):24-34. doi: 10.1016/j.tem.2015.11.003. Epub 2015 Dec 2. Review.

Supplemental Content

Support Center